Page 586 - The Case Lab Book
P. 586
October moves begin to remove Shkreli from Turing board
October New York Attorney General antitrust bureau
investigating Turing: company might be 'unlawfully' restraining
competition.
November Turing said it would cut the price of Daraprim by up
to 50% for some patients.
November Shkreli’s investor group made a 1.2 million share
purchase for a 70% stake in KaloBios Pharmaceuticals Inc.
Shkreli appointed as both CEO and Chairman of KalBios.
th
December 16 Shkreli arrested and charged with securities
fraud and conspiracy and released on a $5 million bond.
KaloBios remove him from the board.
December 17 Shkreli resigns from Turing.
December 29, KaloBios filed for Chapter 11 bankruptcy.
2016 January Shkreli retained criminal defense attorney Benjamin
Brafman
Shkreli subpoenaed to appear before the Committee on
Oversight and Government Reform of the U.S. House of
Representatives
February 4 Shkreli appeared before the House committee
June Shkreli trial date set for 26 June 2017
